12:00 AM
 | 
Jun 16, 2008
 |  BioCentury  |  Strategy

MDRNA chronicles

MDRNA chronicles

The stock price for Nastech, now called MDRNA(NASDAQ:MRNA), has fallen 91% since November 2007, when Procter & Gamble (NYSE:PG) ended a 2006 deal for worldwide rights to intranasal teriparatide to treat osteoporosis. Below are selected events tracked against MDRNA's weekly stock price since the start of 2000. A. 8/9/00 - Nastech acquires Atossa Healthcare, a developer of breast cancer diagnostics and treatments and other women's health products. Steven Quay, the founder of Atossa, becomes chairman, president and CEO of Nastech.

B. 9/26/01 - G. Pohl-Boskampreceives exclusive rights in Europe to develop and market...

Read the full 446 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >